3
Clinical Trials associated with Anti-CD30 CAR T-cell therapy(Bio-Raid)评估靶向 CD30 嵌合抗原受体基因修饰的自体 T 细胞注射液在 CD30 阳性复发/难治性经典型霍奇金淋巴瘤患者中有效性及安全性的 Ⅱ 期临床研究
[Translation] Phase II clinical study to evaluate the efficacy and safety of autologous T cell injection modified with chimeric antigen receptor targeting CD30 in patients with CD30-positive relapsed/refractory classical Hodgkin's lymphoma
第一阶段:评估BRD-01治疗CD30阳性复发/难治性经典型霍奇金淋巴瘤的安全性、耐受性、药代动力学特征和初步有效性。
第二阶段:评估BRD-01治疗CD30阳性复发/难治性经典型霍奇金淋巴瘤受试者的有效性、安全性、药代动力学及药效动力学特征。
[Translation] Phase I: Evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BRD-01 in the treatment of CD30-positive relapsed/refractory classical Hodgkin's lymphoma.
Phase II: Evaluate the efficacy, safety, pharmacokinetics and pharmacodynamic characteristics of BRD-01 in the treatment of CD30-positive relapsed/refractory classical Hodgkin's lymphoma subjects.
靶向CD30嵌合抗原受体基因修饰的自体T细胞注射液在CD30+复发/难治性血液肿瘤患者中安全性及初步疗效的开放标签的Ⅰ期临床研究
[Translation] An open-label phase I clinical study on the safety and preliminary efficacy of autologous T cell injection modified with chimeric antigen receptor targeting CD30 in patients with CD30+ relapsed/refractory hematological malignancies
评价靶向CD30嵌合抗原受体基因修饰的自体T细胞注射液治疗CD30+复发/难治性血液肿瘤患者的安全性。
[Translation] To evaluate the safety of autologous T cell injection modified with chimeric antigen receptor targeting CD30 in the treatment of patients with CD30+ relapsed/refractory hematological malignancies.
Efficacy and Safety of Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies:a Single-center, Open, Single-arm Clinical Study.
The overall purpose of this study is to explore the safety and therapeutic effect of CD30-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of Refractory/Relapsed lymphocyte malignancies.
100 Clinical Results associated with Anti-CD30 CAR T-cell therapy(Bio-Raid)
100 Translational Medicine associated with Anti-CD30 CAR T-cell therapy(Bio-Raid)
100 Patents (Medical) associated with Anti-CD30 CAR T-cell therapy(Bio-Raid)
100 Deals associated with Anti-CD30 CAR T-cell therapy(Bio-Raid)